Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow

BRIDGEWATER, N.J., July 27, 2009 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended June 30, 2009, on Tuesday, August 4, 2009 at approximately 8:00 am Eastern Time (ET).  The release will be followed by a live conference call, which will begin at approximately 9:00 am Eastern Time (ET) on Tuesday, August 4, 2009.

Participating in the call from Enzon’s executive management team will be Jeffrey H. Buchalter, President and Chief Executive Officer, and Craig Tooman, Executive Vice President, Finance and Chief Financial Officer.  

All interested parties may access the call by using the following information:

Domestic Dial-In Number:  (888) 312-3051
International Dial-In Number:  (719) 457-2694
Access Code:    Enzon

The call will also be available via live audio webcast at the following site: http://investor.enzon.com/eventdetail.cfm?eventid=71133.  Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software.  For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event.  Additionally, a telephonic rebroadcast will also be available following the call.  The rebroadcast will begin on Tuesday, August 4, 2009 at approximately 12:00 pm Eastern Time (ET) and end on Tuesday, August 11, 2009 at approximately 12:00 am Eastern Time (ET).  It may be accessed using the following information:

Domestic Dial-In Number:  (888) 203-1112
International Dial-In Number:  (719) 457-0820
Replay Passcode:   3410491

About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology.  Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology.  Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base. Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.

Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should,” "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon’s products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the period ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman
EVP, Finance and Chief Financial Officer
908-541-8777